← Back to Search

Procedure

Hemodilution for Ovarian Cancer

Phase 2
Recruiting
Led By Dennis Chi, MD
Research Sponsored by Memorial Sloan Kettering Cancer Center
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up up to 30 days from procedure
Awards & highlights
No Placebo-Only Group

Summary

This trial will assign participants undergoing primary cytoreductive surgery to receive either acute normovolemic hemodilution (ANH) or standard surgical management. The researchers believe that ANH may reduce

Who is the study for?
This trial is for individuals with ovarian cancer or related conditions who are scheduled for primary cytoreductive surgery. Specific eligibility details aren't provided, but typically participants must meet certain health criteria to ensure safety and the ability to follow the study's procedures.
What is being tested?
The trial is testing acute normovolemic hemodilution (ANH) during surgery against standard surgical management. Participants will be randomly assigned to one of these two approaches to see if ANH can reduce the need for blood transfusions during surgery.
What are the potential side effects?
Potential side effects of ANH may include changes in blood pressure, altered heart rate, imbalances in blood components, or reactions at the site where blood is drawn or returned. The exact side effects will depend on individual responses and procedure outcomes.

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~up to 30 days from procedure
This trial's timeline: 3 weeks for screening, Varies for treatment, and up to 30 days from procedure for reporting.

Treatment Details

Study Objectives

Study objectives can provide a clearer picture of what you can expect from a treatment.
Primary study objectives
Comparison of the rate of allogenic red blood cell transfusions between the Acute Normovolemic Hemodilution (ANH) and standard of care arm

Awards & Highlights

No Placebo-Only Group
All patients enrolled in this study will receive some form of active treatment.

Trial Design

2Treatment groups
Experimental Treatment
Active Control
Group I: Acute Normovolemic Hemodilution (ANH) ArmExperimental Treatment1 Intervention
Group II: Standard Intraoperative Management ArmActive Control1 Intervention

Find a Location

Who is running the clinical trial?

Memorial Sloan Kettering Cancer CenterLead Sponsor
1,979 Previous Clinical Trials
599,757 Total Patients Enrolled
75 Trials studying Ovarian Cancer
43,804 Patients Enrolled for Ovarian Cancer
Dennis Chi, MDPrincipal InvestigatorMemorial Sloan Kettering Cancer Center
6 Previous Clinical Trials
377 Total Patients Enrolled
3 Trials studying Ovarian Cancer
224 Patients Enrolled for Ovarian Cancer
~57 spots leftby Feb 2029
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top